ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

The ubiquitin-proteasome system has recently emerged as a major target for drug development in cancer therapy. The proteasome inhibitor bortezomib has clinical activity in multiple myeloma and mantle cell lymphoma. Here we report that Eeyarestatin I (EerI), a chemical inhibitor that blocks endoplasm...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Wang, Qiuyan, Mora-Jensen, Helena, Weniger, Marc A., Perez-Galan, Patricia, Wolford, Chris, Hai, Tsonwin, Ron, David, Chen, Weiping, Trenkle, William, Wiestner, Adrian, Ye, Yihong
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2009
Teme:
Biological Sciences
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2629785/
https://ncbi.nlm.nih.gov/pubmed/19164757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0807611106
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items